Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Second chance

A California company is reviving a once abandoned treatment for Parkinson's disease. Erika Check assesses its odds of success.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Authors and Affiliations

Authors

Related links

Related links

Related links in Nature Research

Parkinson's trial halted

Direct brain infusion of glial cell line derived neurotrophic factor in Parkinson disease

Profile: Clive Svendsen

The future of gene therapy

Related external links

Ceregene's approach

GDNF 4 Parkinson's advocacy group

Parkinson's Disease Foundation on GDNF research

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Check, E. Second chance. Nat Med 13, 770–771 (2007). https://doi.org/10.1038/nm0707-770

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0707-770

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing